ReviewMicrobiome2018
Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris.
Review in Microbiome, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 310 citations in OpenAlex.
- Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Topical, light-based, and complementary interventions for acne: an overview of systematic reviews.The Cochrane database of systematic reviews · 2024Pooled it
- The Impact of Acne Treatment on Skin Bacterial Microbiota: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Efficacy and safety of combined fractional carbon dioxide laser and topical timolol maleate 0.5% solution versus topical timolol maleate 0.5% solution alone in inflammatory facial acne; a randomized split face controlled study.Lasers in medical science · 2025Trial
- Trial
- 577-nm high-power optically pumped semiconductor laser is safe and effective in the treatment of inflammatory acne: a prospective, single-center, split-face comparative study.European journal of medical research · 2021Trial
- Metal oxide nanoparticles for acne vulgaris: mechanisms, synthesis, formulation, and translational prospects.RSC advances · 2026Review
- Trifarotene for Facial and Truncal Acne Vulgaris: A Narrative Review of Clinical Trial Evidence.Cureus · 2026Review
- Lipid Metabolism, Body Composition, and Diet in Acne Vulgaris: A Narrative Review.Metabolites · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Shotgun Metagenomic Characterization of Acne Microbiota Before and After Treatment with a Topical Biotechnological Phytocomplex: Understanding Skin Dysbiosis.Microorganisms · 2026Article
- Efficacy and safety of oral doxycycline for acne vulgaris treatment: A systematic review and meta-analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Isolation and Genomic Characterization of Two LyticViruses · 2026Article
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds.Health science reports · 2026Article
- Gut and skin dysbiosis in acne vulgaris: a comparative microbiome analysis.Frontiers in cellular and infection microbiology · 2026Article
- Acne vaccine targetingBiotechnologia · 2026Article
- Scalp microbiome in male androgenetic alopecia:Frontiers in cellular and infection microbiology · 2026Article
- Review
- Integrated Metagenomic and Lipidomic Profiling Reveals Dysregulation of Facial Skin Microbiome in Moderate Acne Vulgaris.Microorganisms · 2025Article
- Is There a Place for Biologics in Acne?American journal of clinical dermatology · 2025Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Acne is one of the most common skin diseases worldwide and results in major health care costs and significant morbidity to severely affected individuals. However, the pathophysiology of this disorder is not well understood. Host-microbiome interactions that affect both innate and adaptive immune homeostasis appear to be a central factor in this disease, with recent observations suggesting that the composition and activities of the microbiota in acne is perturbed. Staphylococcus epidermidis and Cutibacterium acnes (C. acnes; formerly Propionibacterium acnes) are two major inhabitants of the skin that are thought to contribute to the disease but are also known to promote health by inhibiting the growth and invasion of pathogens. Because C. acnes is ubiquitous in sebaceous-rich skin, it is typically labeled as the etiological agent of acne yet it fails to fulfill all of Koch's postulates. The outdated model of acne progression proposes that increased sebum production promotes over-proliferation of C. acnes in a plugged hair follicle, thereby driving inflammation. In contrast, growing evidence indicates that C. acnes is equally abundant in both unaffected and acne-affected follicles. Moreover, recent advances in metagenomic sequencing of the acne microbiome have revealed a diverse population structure distinct from healthy individuals, uncovering new lineage-specific virulence determinants. In this article, we review recent developments in the interactions of skin microbes with host immunity, discussing the contribution of dysbiosis to the immunobiology of acne and newly emerging skin microbiome-based therapeutics to treat acne.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.